SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ ADVANCED OR METASTATIC BREAST CANCER (MBC)
Author(s)
Riemsma R1, Forbes CA1, Amonkar M2, Lykopoulos K3, Diaz JR4, Kleijnen J5, Rea DW61Kleijnen Systematic Reviews Ltd, York, North Yorkshire, United Kingdom, 2GlaxoSmithKline, Philadelphia, PA, USA, 3GlaxoSmithKline, London, London, United Kingdom, 4GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom, 5Kleijnen Systematic Reviews Ltd, Escrick, York, United Kingdom, 6Institute for Cancer Studies, Birmingham, Birmingham, United Kingdom
OBJECTIVES: To undertake a systematic review of lapatinib plus letrozole (LAP+LET) with other first line treatments for HR+ HER2+ advanced or MBC in post-menopausal women who have not received prior therapy for advanced or metastatic disease. METHODS: Seven databases were searched through January 2009 for randomized controlled trials. Relevant interventions were lapatinib (alone/in combination), aromatase inhibitors (letrozole (LET), anastrozole (ANA), exemestane (EXE)), tamoxifen (TAM), and trastuzumab (TRAS) (alone/in combination). Outcomes included overall survival (OS), progression free survival (PFS), time to progression (TTP), and objective response rate (ORR). From the available evidence, it was possible to directly compare LAP+LET with LET. Using a network meta-analysis LAP+LET could be indirectly compared with the 4 other interventions. RESULTS: Eighteen studies (62 papers) met the inclusion criteria. LAP+LET was significantly superior to LET based on a direct head to head study in terms of PFS/TTP and ORR. In the indirect comparison with LAP+LET, TAM (Hazard Ratio(HR)=0.45 (95% CI: 0.32, 0.65)), EXE (HR=0.52 (0.34, 0.79)), and ANA (HR=0.53 (0.36, 0.80)) scored significantly worse in terms of PFS/TTP and ORR (TAM: Odds Ratio(OR)=0.25 (0.12, 0.53), ANA: OR=0.27 (0.12, 0.58), EXE: OR=0.47 (0.20, 1.09)). LAP+LET, also seemed better, although not significantly, in terms of OS versus TAM: HR=0.74 (0.49, 1.12), EXE: HR=0.65 (0.39, 1.11), and ANA: HR=0.71 (0.45, 1.14). LAP+LET, when indirectly compared with TRAS+ANA, seemed to be better in terms of OS (HR=0.85 (0.47, 1.54)), PFS/TTP (HR=0.89 (0.54, 1.47)) and ORR (OR=0.92 (0.24, 3.48)), although, none of these results were significant. CONCLUSIONS: Using indirect methods, LAP+LET appeared to be the best treatment in this HR+ HER2+ patient population. However, the results are based on a network analysis for which the basic assumptions of homogeneity, similarity and consistency were not fulfilled. Therefore, despite the fact that these are the best available data, the results need to be interpreted with caution.
Conference/Value in Health Info
2010-11, ISPOR Europe 2010, Prague, Czech Republic
Value in Health, Vol. 13, No. 7 (November 2010)
Code
PCN15
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology